DexCom (DXCM) Stock Price, News & Analysis

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DXCM shares.
View DXCM analyst ratings or view top-rated stocks.

14 equities research analysts have issued 12 month target prices for DexCom's stock. Their DXCM share price targets range from $100.00 to $165.00. On average, they predict the company's share price to reach $141.40 in the next year. This suggests a possible upside of 4.8% from the stock's current price.
View analysts price targets for DXCM or view top-rated stocks among Wall Street analysts.

DexCom's stock was trading at $124.09 on January 1st, 2024. Since then, DXCM stock has increased by 8.7% and is now trading at $134.89.
View the best growth stocks for 2024 here.

DexCom saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 14,570,000 shares, a decline of 8.2% from the March 15th total of 15,870,000 shares. Based on an average daily trading volume, of 3,090,000 shares, the short-interest ratio is currently 4.7 days.
View DexCom's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our DXCM earnings forecast.

DexCom will be holding an earnings conference call on Thursday, April 25th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

DexCom, Inc. (NASDAQ:DXCM) issued its quarterly earnings results on Thursday, February, 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.43 by $0.07. The medical device company had revenue of $1.03 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 14.95% and a trailing twelve-month return on equity of 28.31%. The business's revenue was up 26.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.34 EPS.
Read the conference call transcript.

ETFs with the largest weight of DexCom (NASDAQ:DXCM) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Global X Internet of Things Thematic ETF (SNSR), Subversive Mental Health ETF (SANE), American Century Mid Cap Growth Impact (MID), Fidelity Digital Health ETF (FDHT), Harbor Health Care ETF (MEDI), iShares U.S. Medical Devices ETF (IHI) and Global X Telemedicine & Digital Health ETF (EDOC).

Shares of DexCom split on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly minted shares were payable to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

DexCom updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $4.2 billion-$4.4 billion, compared to the consensus revenue estimate of $4.3 billion.

347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

DexCom's stock is owned by a number of institutional and retail investors. Top institutional investors include Congress Asset Management Co. MA (0.29%), Los Angeles Capital Management LLC (0.09%), AMF Tjanstepension AB (0.02%), Gateway Investment Advisers LLC (0.02%), Czech National Bank (0.02%) and Diversified Trust Co (0.02%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Matthew Vincent Dolan, Michael Jon Brown, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends.

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.